TSHA

Taysha Gene Therapies Inc

Add to Watchlist

Advanced Chart

2.740

+0.12(4.580%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.910

Open

2.700

VWAP

Vol

3.61M

Mkt Cap

690.27M

Low

2.670

Amount

EV/EBITDA(TTM)

Total Shares

187.02M

586.30M

EV/OCF(TTM)

P/S(TTM)

94.15

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

1.51M

-25.51%

1.56M

-12.53%

1.60M

+44.33%

Estimates Revision

The market is revising Upward the revenue expectations for Taysha Gene Therapies, Inc. (TSHA) for FY2025, with the revenue forecasts being adjusted by 32.33% over the past three months. During the same period, the stock price has changed by 41.24%.

Revenue Estimates for FY2025

Revise Upward

+32.33%

In Past 3 Month

Stock Price

Go Up

+41.24%

In Past 3 Month

12 Analyst Rating

203.65% Upside

Wall Street analysts forecast TSHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TSHA is 8.32 USD with a low forecast of 5.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

0 Sell

Strong Buy

203.65% Upside

Current: 2.740

Low

5.00

Averages

8.32

High

13.00

203.65% Upside

Current: 2.740

Low

5.00

Averages

8.32

High

13.00

BofA

NULL -> Buy

initiated

2025-07-11

Reason

BofA

Price Target

2025-07-11

initiated

NULL -> Buy

Reason

BofA initiated coverage of Taysha Gene Therapies with a Buy rating and $8 price target.

BofA

Tazeen Ahmad

Buy

initiated

2025-07-11

Reason

BofA

Tazeen Ahmad

Price Target

2025-07-11

initiated

Buy

Reason

BofA analyst Tazeen Ahmad initiated coverage of Taysha Gene Therapies (TSHA) with a Buy rating and $8 price target. Early data on TSHA-102 for Rett syndrome suggests treated patients can gain/regain developmental milestones, a differentiated result from current options, the analyst tells investors in a research note. The firm is modeling risk-adjusted peak sales for TSHA-102 in Rett syndrome of $995M by 2013, contributing $7/share, and thinks TSHA-102 will challenge Acadia's (ACAD) Daybue, which has a market penetration of 35%.

Craig-Hallum

Albert Lowe

initiated

$50

2025-06-18

Reason

Craig-Hallum

Albert Lowe

Price Target

$50

2025-06-18

initiated

Reason

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Neurogene (NGNE) with a Buy rating and $50 price target. The firm notes the company is developing NGN-401, an AAV gene therapy for Rett syndrome, a rare and devastating neurodevelopmental disease that impacts girls beginning in infancy and is characterized by developmental regression and symptoms that require lifelong care. Craig-Hallum believes Neurogene is undervalued and that NGN-401 has an elegant design that gives it the upper hand over Taysha's (TSHA) competing program TSHA-102. Looking ahead, the firm thinks NGN-401 is well-positioned to show efficacy advantages over TSHA-102 in the second half of 2025 clinical data update and be the leading gene therapy for Rett. This represents a significant commercial opportunity with pricing of over $2M in a U.S. population of about 6k patients, and Albert models WW NGN-401 sales reaching $1B in 2033, including U.S. sales of about $700M.

Cantor Fitzgerald

Kristen Kluska

Overweight

maintain

$7 -> $13

2025-06-11

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$7 -> $13

2025-06-11

maintain

Overweight

Reason

Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target on Taysha Gene Therapies to $13 from $7 and keeps an Overweight rating on the shares. After having attended the IRSF Rett Syndrome Scientific Meeting and spent additional time with Taysha management, the firm has "very high conviction" that the TSHA-102 pivotal trial will succeed, the analyst tells investors. Following data and regulatory path updates, the firm is increasing its view of the odds of success for TSHA-102 to 70% from 35%, the analyst noted.

Canaccord

Buy

maintain

$9 -> $11

2025-06-03

Reason

Canaccord

Price Target

$9 -> $11

2025-06-03

maintain

Buy

Reason

Canaccord raised the firm's price target on Taysha Gene Therapies to $11 from $9 and keeps a Buy rating on the shares. The firm noted the company shared both a regulatory and a clinical update (longer term low-dose follow-up data and first look at high-dose data) for its TSHA-102 program for Rett Syndrome. Canaccord updated its model for the updates, namely increasing their assigned POS on TSHA-102 to 75% from 50% previously and the roughly $200M offering via a mix of shares and prefunded warrants.

Needham

Buy

maintain

$6 -> $8

2025-06-02

Reason

Needham

Price Target

$6 -> $8

2025-06-02

maintain

Buy

Reason

Needham raised the firm's price target on Taysha Gene Therapies to $8 from $6 and keeps a Buy rating on the shares after Taysha last week reported updated clinical data from the adult/pediatric REVEAL studies and details on an FDA-aligned pivotal study. Evidence of dose-dependence is further de-risking for TSHA-102 and the firm views this update as "a win across the board," the analyst tells investors.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Taysha Gene Therapies Inc (TSHA.O) is -7.89, compared to its 5-year average forward P/E of -4.10. For a more detailed relative valuation and DCF analysis to assess Taysha Gene Therapies Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.10

Current PE

-7.89

Overvalued PE

-1.72

Undervalued PE

-6.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.68

Current EV/EBITDA

-5.11

Overvalued EV/EBITDA

0.68

Undervalued EV/EBITDA

-8.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

27.89

Current PS

94.08

Overvalued PS

59.07

Undervalued PS

-3.29